Longeveron (LGVN) Shares Outstanding (Weighted Average) (2020 - 2026)

Longeveron (LGVN) recorded quarterly Shares Outstanding (Weighted Average) of $24.8 billion in Q1 2026, up 41.02% quarter-over-quarter from $17.6 billion in Q4 2025, and up 364261.19% on a YoY basis from N/an in Q1 2025.

Longeveron (LGVN) Shares Outstanding (Weighted Average) (2020 - 2026) Analysis & Trends

Longeveron's Shares Outstanding (Weighted Average) history runs 7 years deep, the most recent figure standing at $24.8 billion for Q1 2026.

  • In Q1 2026, Shares Outstanding (Weighted Average) rose 364261.19% year-over-year to $24.8 billion; the TTM figure through Mar 2026 stood at $24.8 billion (up 364261.19% YoY), while the FY2025 annual figure was $17.6 billion, up 785962.01% from the prior year.
  • Shares Outstanding (Weighted Average) was $24.8 billion for Q1 2026 at Longeveron, up from $17.6 billion in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $24.8 billion in Q1 2026 to a low of $242425.0 in Q1 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $4.7 billion across 5 years, with a median of $20.9 million in 2022.
  • The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Weighted Average) sank 89.94% in 2023, then surged 364261.19% in 2026.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $21.0 million in 2022, then jumped by 10265.24% to $2.2 billion in 2023, then surged by 333.0% to $9.4 billion in 2024, then surged by 86.76% to $17.6 billion in 2025, then jumped by 41.02% to $24.8 billion in 2026.
  • The last three Shares Outstanding (Weighted Average) figures came in at $24.8 billion (Q1 2026), $17.6 billion (Q4 2025), and $18.4 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 185,491.37 Bn
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 400.00 Bn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 4,489.46 Bn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 100.00 Bn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 417.01 Bn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 118.76 Bn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 68.88 Bn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 254.10 Mn
9 Abivax 91.96 Bn 91.96 Bn - 928.40 Mn
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00 24.79 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 24.79 Bn
Dec 31, 2025 17.58 Bn
Sep 30, 2025 18.37 Bn
Jun 30, 2025 242,425.00
Mar 31, 2025 6.80 Mn
Dec 31, 2024 9.41 Bn
Sep 30, 2024 7.57 Bn
Jun 30, 2024 242,425.00
Mar 31, 2024 242,425.00
Dec 31, 2023 2.17 Bn
Sep 30, 2023 2.42 Mn
Jun 30, 2023 2.11 Mn
Mar 31, 2023 2.10 Mn
Dec 31, 2022 20.97 Mn
Sep 30, 2022 20.95 Mn
Jun 30, 2022 20.94 Mn
Mar 31, 2022 20.91 Mn
Dec 31, 2021 18.92 Mn
Sep 30, 2021 18.54 Mn
Jun 30, 2021 19.01 Mn